Overview

A Study of Standard Drugs for Mycobacterium Avium Complex

Status:
Recruiting
Trial end date:
2022-05-10
Target enrollment:
Participant gender:
Summary
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Azithromycin